



**Milestone**<sup>TM</sup>  
PHARMACEUTICALS

## **Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference**

September 7, 2021

MONTREAL and CHARLOTTE, N.C., Sept. 7, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 23<sup>rd</sup> Annual Global Investment Conference being held virtually on September 13-15, 2021.

The prerecorded fireside chat will become available on Monday, September 13, 2021 at 7:00am ET and can be accessed in the News & Events section of Milestone's website at [www.milestonepharma.com](http://www.milestonepharma.com). An archived replay of the fireside chat will be available on the same website 90 days following the presentation.

### **About Milestone Pharmaceuticals**

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit [www.milestonepharma.com](http://www.milestonepharma.com) and follow the Company on Twitter at @MilestonePharma.

### **Contact**

David Pitts  
Argot Partners  
212-600-1902  
[david@argotpartners.com](mailto:david@argotpartners.com)



**Milestone**<sup>TM</sup>  
PHARMACEUTICALS

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301369385.html>

SOURCE Milestone Pharmaceuticals, Inc.